Montanova Capital, LLC
13F filer · CIK 0001569064Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$5.47BU.S. long equity reported on 13F
Positions9421 new · 14 closed
Net flow last quarter+$133MBuys minus sells
Top 10 positions weight38.8%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202694 positions | |||||
| $513M | 9.37% | 9.98% | Not reported | Q1 2026 | |
| $326M | 5.96% | 9.90% | +0.9% | Q1 2023 | |
| $204M | 3.73% | 1.91% | -6.7% | Q2 2020 | |
| $174M | 3.17% | 7.89% | -1.6% | Q4 2024 | |
| $157M | 2.87% | 9.35% | +2.6% | Q1 2024 | |
| $155M | 2.83% | 33.55% | Not reported | Q2 2021 | |
| $153M | 2.80% | 6.81% | Not reported | Q1 2022 | |
| $149M | 2.73% | 0.02% | Not reported | Q4 2022 | |
| $147M | 2.69% | 3.76% | -5.1% | Q3 2023 | |
| $145M | 2.66% | 0.00% | +2.0% | Q2 2023 | |
| $144M | 2.64% | 0.00% | +25.4% | Q4 2022 | |
| $119M | 2.17% | 9.76% | Not reported | Q1 2021 | |
| $118M | 2.16% | 0.30% | +21.8% | Q1 2019 | |
| $116M | 2.12% | 0.03% | Not reported | Q2 2023 | |
| $113M | 2.07% | 8.35% | Not reported | Q1 2024 | |
| $111M | 2.03% | 0.92% | +7.7% | Q4 2025 | |
| $99M | 1.81% | Not reported | +3.6% | Q4 2014 | |
| $98.6M | 1.80% | 7.04% | +7.2% | Q4 2025 | |
| $94.1M | 1.72% | 9.64% | Not reported | Q3 2020 | |
| $85.9M | 1.57% | 4.16% | -16.0% | Q2 2021 | |
| $82.4M | 1.51% | 5.65% | New | Q2 2026 | |
| $79.7M | 1.46% | 0.02% | +2.0% | Q4 2016 | |
| $77.3M | 1.41% | 0.54% | New | Q2 2026 | |
| $66.8M | 1.22% | 0.05% | +10.2% | Q4 2016 | |
| $63.4M | 1.16% | 0.17% | +18.4% | Q1 2026 | |
| $58.6M | 1.07% | 0.13% | +16.5% | Q4 2023 | |
| $55.7M | 1.02% | 9.90% | +4.2% | Q2 2023 | |
| $51.4M | 0.94% | 31.72% | +189.1% | Q1 2021 | |
| $51.2M | 0.94% | 6.96% | +64.8% | Q1 2025 | |
| $50.5M | 0.92% | 7.82% | +5747.1% | Q1 2026 | |
| $48.8M | 0.89% | 0.00% | -19.4% | Q1 2016 | |
| $48.6M | 0.89% | 5.23% | +4.0% | Q4 2025 | |
| $47.5M | 0.87% | 0.02% | Not reported | Q2 2020 | |
| $46.7M | 0.85% | 0.05% | +9154.6% | Q2 2019 | |
| $46.6M | 0.85% | 12.30% | Not reported | Q2 2024 | |
| $45.3M | 0.83% | 0.07% | -1.1% | Q3 2023 | |
| $45M | 0.82% | 0.01% | -39.0% | Q1 2018 | |
| $44.5M | 0.81% | Not reported | New | Q2 2026 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $44.4M | 0.81% | 1.12% | +13.6% | Q2 2022 |
| $38M | 0.69% | Not reported | New | Q2 2026 | |
| $34.3M | 0.63% | 0.16% | Not reported | Q2 2025 | |
| $31.6M | 0.58% | 0.00% | New | Q2 2026 | |
| $30.9M | 0.56% | 7.83% | -1.4% | Q2 2025 | |
| $29.7M | 0.54% | 8.12% | +410.7% | Q4 2025 | |
| $26.7M | 0.49% | 0.01% | -36.3% | Q4 2016 | |
| $25.2M | 0.46% | Not reported | Not reported | Q3 2022 | |
| $19.7M | 0.36% | 7.54% | +16.2% | Q1 2025 | |
| $17.3M | 0.32% | Not reported | New | Q2 2026 | |
| $15M | 0.27% | 0.04% | New | Q2 2026 | |
| $13.5M | 0.25% | 4.83% | -43.9% | Q1 2021 | |
| Q1 2026Reported May 15, 202687 positions | |||||
| $290M | 7.42% | 9.86% | +3.0% | Q1 2023 | |
| $263M | 6.72% | 11.16% | New | Q1 2026 | |
| $144M | 3.67% | 8.06% | +29.3% | Q4 2024 | |
| APAPLSApellis Pharmaceuticals, Inc. | $142M | 3.62% | 2.75% | -15.0% | Q1 2020 |
| $137M | 3.50% | 2.05% | +14.7% | Q2 2020 | |
| $123M | 3.14% | 33.62% | Not reported | Q2 2021 | |
| $116M | 2.97% | 6.62% | +113.9% | Q4 2025 | |
| $110M | 2.81% | 8.35% | Not reported | Q1 2024 | |
| $109M | 2.78% | 4.01% | -3.0% | Q3 2023 | |
| $107M | 2.73% | 9.94% | +6.0% | Q1 2021 | |
| $102M | 2.59% | 9.71% | +7.2% | Q1 2024 | |
| $101M | 2.58% | 0.00% | +10.1% | Q2 2023 | |
| $100M | 2.56% | 0.00% | +8.2% | Q4 2022 | |
| $97.1M | 2.48% | Not reported | +0.4% | Q4 2014 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $96M | 2.45% | 9.31% | Not reported | Q1 2020 |
| $88M | 2.25% | 0.03% | Not reported | Q2 2023 | |
| $87M | 2.22% | 6.83% | Not reported | Q1 2022 | |
| $82.7M | 2.11% | 0.24% | +7.0% | Q1 2019 | |
| $79.9M | 2.04% | 0.84% | +79.6% | Q4 2025 | |
| $75.7M | 1.93% | 7.94% | +0.9% | Q2 2025 | |
| $72.9M | 1.86% | 0.02% | -8.0% | Q4 2016 | |
| $69.7M | 1.78% | 9.66% | Not reported | Q3 2020 | |
| $69.5M | 1.78% | 5.01% | +25.8% | Q2 2021 | |
| $63.1M | 1.61% | 0.02% | -14.7% | Q1 2018 | |
| $55.6M | 1.42% | 1.11% | -76.3% | Q2 2024 | |
| $55.2M | 1.41% | 0.05% | +75.8% | Q4 2016 | |
| $53.9M | 1.38% | 9.56% | +62.9% | Q2 2023 | |
| $52.9M | 1.35% | 0.00% | -37.5% | Q1 2016 | |
| $52.3M | 1.34% | 0.02% | -34.0% | Q4 2022 | |
| $50.3M | 1.29% | 9.85% | Not reported | Q1 2021 | |
| $49.4M | 1.26% | 0.14% | New | Q1 2026 | |
| $49.4M | 1.26% | 0.11% | +33.1% | Q4 2023 | |
| $43.2M | 1.10% | 0.07% | -28.6% | Q3 2023 | |
| $41.7M | 1.06% | 1.87% | Not reported | Q1 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $37.9M | 0.97% | 0.99% | Not reported | Q2 2022 |
| $37.1M | 0.95% | 12.30% | Not reported | Q2 2024 | |
| $36.5M | 0.93% | 0.18% | Not reported | Q3 2016 | |
| $33.1M | 0.85% | 0.25% | New | Q1 2026 | |
| $32.3M | 0.82% | 5.10% | +11615.0% | Q4 2025 | |
| $29.3M | 0.75% | 6.82% | Not reported | Q1 2025 | |
| $27.2M | 0.70% | 0.01% | -9.6% | Q4 2016 | |
| $22.1M | 0.56% | Not reported | Not reported | Q3 2022 | |
| $13.7M | 0.35% | 0.23% | New | Q1 2026 | |
| $12.8M | 0.33% | 7.84% | Not reported | Q1 2025 | |
| $12M | 0.31% | 4.71% | Not reported | Q2 2024 | |
| $9.22M | 0.24% | 0.22% | Not reported | Q2 2025 | |
| $8.82M | 0.23% | 5.50% | Not reported | Q2 2021 | |
| $7.78M | 0.20% | 0.01% | -64.9% | Q3 2018 | |
| $7.18M | 0.18% | 1.69% | Not reported | Q4 2025 | |
| $7.15M | 0.18% | 0.02% | -78.3% | Q4 2025 | |
| Q4 2025Reported Feb 17, 202689 positions | |||||
| $347M | 7.12% | 9.70% | +14.2% | Q1 2023 | |
| $156M | 3.19% | 33.71% | +16.9% | Q2 2021 | |
| $144M | 2.94% | 1.79% | +73.1% | Q2 2020 | |
| $143M | 2.93% | 9.45% | +26.4% | Q1 2021 | |
| $124M | 2.53% | 4.14% | +40.7% | Q3 2023 | |
| $117M | 2.41% | 8.35% | -7.0% | Q1 2024 | |
| $116M | 2.38% | 7.75% | +83.0% | Q1 2022 | |
| $112M | 2.29% | Not reported | -1.1% | Q4 2014 | |
| APAPLSApellis Pharmaceuticals, Inc. | $104M | 2.13% | 3.27% | +43.8% | Q1 2020 |
| $99M | 2.03% | 0.00% | +9.8% | Q4 2022 | |
| $96.7M | 1.98% | 0.03% | -5.0% | Q1 2024 | |
| $95.6M | 1.96% | 0.03% | Not reported | Q2 2023 | |
| $93.7M | 1.92% | 0.00% | +85.8% | Q1 2016 | |
| $93.4M | 1.91% | 7.21% | +8.5% | Q4 2024 | |
| $89.1M | 1.83% | 9.76% | +5.7% | Q3 2020 | |
| $83.5M | 1.71% | 0.02% | +30.8% | Q1 2018 | |
| $83.4M | 1.71% | 0.02% | -2.3% | Q4 2022 | |
| $82.9M | 1.70% | 0.02% | +22.1% | Q4 2016 | |
| $82.6M | 1.69% | 9.67% | +10.9% | Q1 2024 | |
| $82.5M | 1.69% | 0.00% | -2.1% | Q2 2023 | |
| $79.9M | 1.64% | 0.23% | Not reported | Q1 2019 | |
| $78.6M | 1.61% | 0.09% | +25.9% | Q3 2023 | |
| $77.2M | 1.58% | 0.00% | +45.9% | Q4 2015 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $77M | 1.58% | 9.37% | Not reported | Q1 2020 |
| $76.2M | 1.56% | 7.95% | +0.6% | Q2 2025 | |
| $74.2M | 1.52% | 9.85% | +21.9% | Q1 2021 | |
| $59.7M | 1.22% | 0.04% | +254.0% | Q3 2019 | |
| $55.9M | 1.15% | 0.03% | -4.5% | Q3 2014 | |
| $55.8M | 1.14% | 1.89% | -27.8% | Q1 2025 | |
| $53.9M | 1.11% | 5.10% | Not reported | Q2 2024 | |
| $53M | 1.08% | 0.02% | +59.6% | Q4 2016 | |
| $52.7M | 1.08% | 5.13% | Not reported | Q2 2021 | |
| $51.5M | 1.06% | 3.11% | New | Q4 2025 | |
| $46.4M | 0.95% | 2.09% | Not reported | Q4 2021 | |
| $44.1M | 0.90% | 0.01% | Not reported | Q4 2022 | |
| $43.9M | 0.90% | 0.47% | New | Q4 2025 | |
| $41.7M | 0.85% | 0.03% | -28.0% | Q4 2016 | |
| $41M | 0.84% | 0.00% | Not reported | Q2 2024 | |
| $36.7M | 0.75% | 0.01% | +15.7% | Q4 2016 | |
| $35.4M | 0.73% | 0.08% | -48.0% | Q4 2023 | |
| $33.7M | 0.69% | 0.02% | Not reported | Q3 2018 | |
| $32.5M | 0.67% | 12.30% | +65.2% | Q2 2024 | |
| $29.2M | 0.60% | 7.56% | +1.7% | Q2 2023 | |
| $29.1M | 0.60% | 1.95% | New | Q4 2025 | |
| $27.6M | 0.57% | Not reported | Not reported | Q3 2022 | |
| $25.5M | 0.52% | 0.09% | New | Q4 2025 | |
| $25.4M | 0.52% | 0.05% | Not reported | Q1 2020 | |
| $23.8M | 0.49% | 6.88% | Not reported | Q1 2025 | |
| $23.6M | 0.48% | 1.96% | New | Q4 2025 | |
| $23.3M | 0.48% | 0.09% | -21.3% | Q1 2020 | |
| Q3 2025Reported Nov 14, 202589 positions | |||||
| $198M | 5.06% | 8.71% | -9.2% | Q1 2023 | |
| $139M | 3.55% | 37.62% | Not reported | Q2 2021 | |
| $126M | 3.21% | Not reported | +0.7% | Q4 2014 | |
| $125M | 3.19% | 1.04% | +1.2% | Q2 2020 | |
| 8ETNB89bio, Inc. | $122M | 3.12% | 5.58% | -41.7% | Q1 2023 |
| $102M | 2.62% | 9.90% | Not reported | Q1 2024 | |
| $96.5M | 2.47% | 0.03% | +18.0% | Q1 2024 | |
| $93.3M | 2.39% | 0.03% | Not reported | Q2 2023 | |
| $90.2M | 2.31% | 0.00% | -3.2% | Q4 2022 | |
| $88.2M | 2.26% | 8.90% | -9.0% | Q1 2021 | |
| $84.4M | 2.16% | 5.31% | Not reported | Q1 2022 | |
| $80.9M | 2.07% | 2.70% | +22.2% | Q1 2025 | |
| $79.9M | 2.05% | 0.02% | +50.9% | Q4 2016 | |
| $77.4M | 1.98% | 0.00% | -7.7% | Q2 2023 | |
| $71.8M | 1.84% | 9.33% | Not reported | Q3 2020 | |
| $68.8M | 1.76% | 0.16% | +61.5% | Q4 2023 | |
| $68.3M | 1.75% | 9.07% | +8.5% | Q1 2024 | |
| APAPLSApellis Pharmaceuticals, Inc. | $65.1M | 1.67% | 2.28% | Not reported | Q1 2020 |
| $64.5M | 1.65% | 0.02% | Not reported | Q4 2022 | |
| $63.6M | 1.63% | 0.01% | -1.9% | Q4 2022 | |
| $60.7M | 1.55% | 2.09% | -11.4% | Q4 2021 | |
| $59.9M | 1.53% | 0.02% | +25.1% | Q1 2018 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $58.1M | 1.49% | 9.44% | -3.8% | Q1 2020 |
| $57.5M | 1.47% | 0.07% | +0.7% | Q3 2023 | |
| $56.7M | 1.45% | 0.00% | +10.8% | Q4 2015 | |
| $51.6M | 1.32% | 7.42% | +15.1% | Q4 2024 | |
| $50.8M | 1.30% | 0.04% | +23.0% | Q4 2016 | |
| $50.7M | 1.30% | 0.04% | +46.4% | Q3 2014 | |
| $50.2M | 1.28% | 3.44% | Not reported | Q3 2023 | |
| $49.5M | 1.27% | 9.94% | +5.9% | Q1 2021 | |
| $49.4M | 1.26% | 7.94% | +97.2% | Q2 2025 | |
| $48M | 1.23% | 0.00% | -15.2% | Q1 2016 | |
| $40.6M | 1.04% | 0.00% | -1.2% | Q2 2024 | |
| $40.1M | 1.03% | 0.12% | Not reported | Q3 2024 | |
| $34.5M | 0.88% | 0.02% | Not reported | Q3 2018 | |
| $33.2M | 0.85% | 0.01% | +41.5% | Q4 2016 | |
| ABRNAMAvidity Biosciences, Inc. | $32.7M | 0.84% | 0.51% | New | Q3 2025 |
| $31.6M | 0.81% | 5.11% | Not reported | Q2 2024 | |
| $31.4M | 0.80% | 0.10% | -8.8% | Q1 2020 | |
| $29.9M | 0.76% | Not reported | Not reported | Q3 2022 | |
| $29.7M | 0.76% | 0.01% | Not reported | Q4 2016 | |
| $28.5M | 0.73% | 0.14% | -50.8% | Q2 2025 | |
| $27M | 0.69% | 6.94% | Not reported | Q1 2025 | |
| $24.9M | 0.64% | 5.44% | Not reported | Q2 2021 | |
| $24.6M | 0.63% | 0.01% | Not reported | Q4 2019 | |
| $23.7M | 0.61% | 8.42% | +12.6% | Q2 2023 | |
| $23.6M | 0.60% | 0.11% | +10.7% | Q1 2020 | |
| $22.9M | 0.59% | 0.03% | Not reported | Q1 2023 | |
| $20.2M | 0.52% | 0.01% | Not reported | Q3 2019 | |
| $20.2M | 0.52% | 6.13% | Not reported | Q2 2024 | |
Premium opens every quarter this fund has filed